Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | SCN4A | P35499 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450749 | 1.00 | GAA (0.63) | GAAS1PR5NPC1RAB9ALTA4H | |
| SCHEMBL6286609 | 1.00 | GAA (0.63) | GAAS1PR5NPC1RAB9ALTA4H | |
| SCHEMBL3157551 | 0.91 | GAA (0.61) | GAAS1PR5NPC1RAB9ALTA4H | |
| SCHEMBL2444402 | 0.91 | GAA (0.77) | GAANPC1RAB9ALTA4HMEN1 | |
| SCHEMBL3314498 | 0.91 | GAA (0.77) | GAANPC1RAB9ALTA4HMEN1 | |
| SCHEMBL518686 | 0.90 | NPC1 (0.71) | GAANPC1RAB9AMEN1TSHR | |
| SCHEMBL8318203 | 0.90 | GAA (0.58) | GAAS1PR5NPC1RAB9ASCN4A | |
| Hydrochloric Acid SCHEMBL8324757 | 0.89 | GAA (0.57) | GAAS1PR5NPC1RAB9ASCN4A | |
| Hydrochloric Acid SCHEMBL5712502 | 0.89 | NPC1 (0.70) | GAANPC1RAB9AMEN1TSHR | |
| SCHEMBL9037650 | 0.87 | S1PR5 (0.77) | S1PR5LTA4HSCN4AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071436-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20220340557-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-27 | — | — | US | disclosed |
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2017124087-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2009102325-A1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20050171183-A1 | Indole-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6890938-B2 | Indole-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | GAA 17/4885S1PR5 553/4885NPC1 539/4885 |
| US-12071436-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | GAA 17/4885S1PR5 553/4885NPC1 539/4885 |
| US-20220340557-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | GAA 17/4885S1PR5 553/4885NPC1 539/4885 |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | GAA 17/4885S1PR5 553/4885NPC1 539/4885 |
| US-20050171183-A1 | Indole-type inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAP3K1 | GAA 4527/4885S1PR5 2021/4885NPC1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.